Key result
Among patients with LBBB, CRT-D was associated with a lower mortality risk than ICD in women and men, with greater benefit in women.
Why the study?
Does cardiac resynchronization therapy-defibrillator (CRT-D) reduce death risk compared to implantable cardioverter defibrillator (ICD) in patients with NYHA class III/IV heart failure, reduced LVEF, and prolonged QRS duration?
Cohort (n=75,079)
Does cardiac resynchronization therapy-defibrillator (CRT-D) reduce death risk compared to implantable cardioverter defibrillator (ICD) in patients with NYHA class III/IV heart failure, reduced LVEF, and prolonged QRS duration?
In a large real-world cohort, CRT-D was associated with a greater mortality reduction in women than in men among patients with LBBB, while benefits were attenuated in both sexes without LBBB.
Answers are grounded in this paper and cite their sources.
Greater CRT-D mortality benefit in women with LBBB; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Women have been under-represented in trials of cardiac resynchronization therapy-defibrillators (CRT-D). Previous studies suggest that women benefit from CRT-D at shorter QRS duration than men and that there may be no benefit of CRT-D in patients without left bundle branch block (LBBB) regardless of patient sex. METHODS AND RESULTS: We compared sex-specific death risk in 75 079 patients with New York Heart Association class III or IV heart failure, reduced left ventricular ejection fraction, and prolonged QRS duration (≥120 ms) receiving either CRT-D or implantable cardioverter defibrillator in subgroups according to QRS morphology and 10-ms increments in QRS duration. We applied propensity score weighting to control for differences between treatments. Among patients with LBBB, women receiving CRT-D had a lower relative death risk than those receiving an implantable cardioverter-defibrillator (absolute difference, 11%; hazard ratio=0.74 [95% confidence interval, 0.68-0.81]). In men, the lower mortality with CRT-D versus implantable cardioverter defibrillator was less pronounced (absolute difference, 9%; hazard ratio=0.84 [0.79-0.89]; sex×device interaction P=0.025). In those without LBBB, the mortality difference was modest and did not differ between women and men (absolute difference, 3%; hazard ratio=0.88 [0.79-0.97] in women and absolute difference, 2%; hazard ratio=0.95 [0.91-0.998] in men; interaction P=0.17). In subgroups according to QRS duration, CRT-D was associated with better survival in both sexes with LBBB and QRS ≥130 ms, whereas there was no clear relation between QRS duration and survival in patients without LBBB regardless of patient sex. CONCLUSIONS: In a large real-world population CRT-D was associated with a lower mortality risk in both sexes with LBBB, although more pronounced among women. Only among those with LBBB, both sexes had better survival with longer QRS duration. The mortality differences in patients without LBBB were attenuated in both sexes.
No takes yet. Share an insight, caveat, or question.
Zusterzeel et al. (2015) conducted a cohort in Heart failure with reduced ejection fraction and prolonged QRS duration (n=75,079). Cardiac resynchronization therapy-defibrillators (CRT-D) vs. Implantable cardioverter defibrillator (ICD) was evaluated on Death risk (HR 0.74, 95% CI 0.68-0.81). Among patients with LBBB, CRT-D was associated with a lower mortality risk than ICD in women and men, with greater benefit in women.
Synapse has enriched 10 related papers. Consider them for comparative context: